The Biden administration has inked a deal with the North American arm of a German pharmaceutical company to build a plant in Wisconsin that will produce lateral flow membranes used in rapid diagnostic test kits, including ones used to detect COVID-19. But the facility won’t be built for another three years and so the move won’t help alleviate America’s current test kit shortage.
“This industrial base expansion effort will allow MilliporeSigma to establish a nitrocellulose manufacturing capability in its Sheboygan, Wisconsin facility to support more than 83.3 million tests per month for COVID-19 testing and future needs,” the DoD said.
Money for the plant will come from American Rescue Plan Act (ARPA) allocations to support the expansion of the U.S. industrial base for critical medical resources.
President Joe Biden announced earlier in December that the federal government would buy half a million COVID-19 rapid test kits and distribute them free of charge for people to use at home.
“That means that the first deliveries for manufacturers will start January,” Zients said. “We’ll set up a free and easy system, including a new website to get these tests out to Americans. We’re actively working to finalize that distribution mechanism, which includes a website where people will be able to order tests for free.”
Some experts believe that those figures are actually higher and that a testing crunch is leading to the under-capturing of infection data.